Description

7,8-Dichloro-2,3,4A,10A-Tetrahydro[1,4]Dioxino[2,3-G]Quinoxaline is a high-purity, advanced pharmaceutical intermediate characterized by its complex fused heterocyclic structure. This compound is of significant value in medicinal chemistry for the research and development of novel therapeutic agents, particularly within the central nervous system (CNS) and oncology fields. It is primarily sought after by pharmaceutical R&D laboratories, custom synthesis providers, and manufacturers of active pharmaceutical ingredients (APIs) for its role as a key synthetic building block.

Application

• Pharmaceutical Intermediate: A critical precursor in the multi-step synthesis of complex drug candidates and novel chemical entities (NCEs).
• Medicinal Chemistry Research: Used as a core scaffold or building block for structure-activity relationship (SAR) studies in drug discovery programs.
• CNS Drug Development: Serves as a key intermediate in the synthesis of potential therapeutics targeting neurological and psychiatric disorders.
• Oncological Agent Synthesis: Employed in the research and development pathways for novel anti-cancer compounds.
• Custom Synthesis & Contract Manufacturing: Supplied to CDMOs (Contract Development and Manufacturing Organizations) for the production of bespoke molecules and APIs under GMP conditions.
• Academic & Institutional Research: Utilized in university and institutional labs for advanced organic synthesis and pharmacological studies.

Basic Information

Product Name	7,8-Dichloro-2,3,4A,10A-Tetrahydro[1,4]Dioxino[2,3-G]Quinoxaline
CAS No.	727704-79-2
Molecular Formula	C12H10Cl2N2O2
Molecular Weight	285.13 g/mol
Synonyms	7,8-Dichloro-2,3,4a,10a-tetrahydro-[1,4]dioxino[2,3-g]quinoxaline; [1,4]Dioxino[2,3-g]quinoxaline, 7,8-dichloro-2,3,4a,10a-tetrahydro-; 7,8-Dichloro-2,3,4a,10a-tetrahydro-1,4-dioxino[2,3-g]quinoxaline; Tetrahydrodioxinoquinoxaline derivative; Dioxinoquinoxaline intermediate
EINECS	Contact for details

Quality Control

Our 7,8-Dichloro-2,3,4A,10A-Tetrahydro[1,4]Dioxino[2,3-G]Quinoxaline is manufactured under strict quality management systems. Every batch undergoes rigorous analytical testing, including HPLC, NMR, and mass spectrometry, to ensure identity, purity, and consistency. We provide comprehensive Certificates of Analysis (COA) with each shipment, detailing all critical quality attributes. Our production can be aligned with cGMP (current Good Manufacturing Practice) standards for pharmaceutical applications upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (typically 15-25°C). This compound is light-sensitive (store away from light) and may be hygroscopic (moisture-sensitive); therefore, containers should be kept sealed under an inert atmosphere if specified for long-term storage.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Related Substances (HPLC)	Any single impurity ≤ 0.5%, Total impurities ≤ 2.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.